Signal brief

The guidance cut is severe and incentivizes immediate repricing. The prior fiscal 2025 midpoint ((268+275)/2 = $271.5M) versus the new midpoint ((192+193)/2 = $192.5M) implies an approximate 29% reduction in top‑line expectations, and Q4 guidance at ~$45.5M versus a ~$63.07M consensus is ~28% below estimates. Those magnitudes generally force multiple contraction for small‑cap growth/telehealth names and reduce near‑term free‑cash‑flow visibility. Operational positives (13% revenue growth, 20% adjusted EBITDA growth, telehealth EBITDA expansion, and debt payoff) are creditworthy but insufficient to offset a material downward revision to FY revenue that underpins valuation. Historically, small‑cap telehealth and digital health firms that cut guidance materially are re‑rated lower—investor reactions commonly range from 20% to 50% intraday/short‑term declines—because forward multiples compress and investor confidence erodes. The significant guidance miss therefore signals downside pressure on LFMD shares until management re‑establishes credible growth visibility.